Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Tanya Skamene, MD, Wenyu Jiang, PhD, Ralph M. Meyer, MD, Michael Crump, MD, John Kuruvilla, MD, C. Tom Kouroukis, MD MSc, FRCPC, Stefano Luminari, Stephen Couban, MD, Matthew C. Cheung, MD SM, FRCPC, David A Rizzieri, MD, Peter G Bardy, MBBS, FRACP, FRCPA, Joseph Pater, MD MSc, Marina S. Djurfeldt, MSc, Lois E. Shepherd, MD, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 690.

https://doi.org/10.1182/blood.V128.22.690.690

Published: 2016

Journal Articles

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma

Ming Han, Alli Murugesan, Nizar J. Bahlis, Kevin Song, Darrell White, Christine Chen, Matthew D. Seftel, Kang Howsen-Jan, Donna Reece, Keith Stewart, Yagang Xie, Annette E. Hay, Lois Shepherd, Marina Djurfeldt, Liting Zhu, Ralph M. Meyer, Bingshu E. Chen, Tony Reiman

Blood (2016) 128 (5): 732–735.

https://doi.org/10.1182/blood-2016-06-716902

Published: 2016

Includes: Supplemental data

Journal Articles

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Michael J. Kelly, MD MPH, MS, Susan K Parsons, MDMRP, David C. Hodgson, MD, Joshua T Cohen, PhD, Jennifer M Yeh, MD PhD, Jeremy S. Abramson, MD, Debra L. Friedman, MD MS, Tara O Henderson, MDMPH, Peter W Johnson, MD, Stephen G Pauker, MD, John M. Raemaekers, MD PhD, Jane N. Winter, MD, Kara M. Kelly, MD, Ralph M. Meyer, MD, Sharon M Castellino, MD, Andrew M. Evens, DO, MSc

Blood (2015) 126 (23): 2635.

https://doi.org/10.1182/blood.V126.23.2635.2635

Published: 2015

Journal Articles

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

John Kuruvilla, David A. MacDonald, C. Tom Kouroukis, Matthew Cheung, Harold J. Olney, A. Robert Turner, Peter Anglin, Matthew Seftel, Walid Sabry Ismail, Stefano Luminari, Stephen Couban, Tara Baetz, Ralph M. Meyer, Annette E. Hay, Lois Shepherd, Marina S. Djurfeldt, Sameer Alamoudi, Bingshu E. Chen, Michael Crump

Blood (2015) 126 (6): 733–738.

https://doi.org/10.1182/blood-2015-01-622084

Published: 2015

Journal Articles

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Tara Baetz, MD, Bingshu E Chen, PhD, Stephen Couban, MD, C. Tom Kouroukis, MD MSc, FRCPC, Rena Buckstein, MD, John Kuruvilla, MD, Kang Howson-Jan, David Szwajcer, MD FRCPC, Massimo Federico, MD, Ralph M. Meyer, Robert Turner, MD, Marina S Djurfeldt, MSc, Annette E Hay, MB ChB, Lois Shepherd, MD, Michael Crump, MD

Blood (2014) 124 (21): 1712.

https://doi.org/10.1182/blood.V124.21.1712.1712

Published: 2014

Journal Articles

Interpretation and Application of the International Myeloma Working Group (IMWG) Criteria: Proposal for Uniform Assessment and Reporting in Clinical Trials Based on the First Study Independent Response Adjudication Committee (IRAC) Experience

Joan Blade, Stefan Knop, MD, Adam D. Cohen, MD, Jatin J. Shah, Ralph M. Meyer

Blood (2014) 124 (21): 3460.

https://doi.org/10.1182/blood.V124.21.3460.3460

Published: 2014

Journal Articles

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

Blood (2013) 122 (21): 155.

https://doi.org/10.1182/blood.V122.21.155.155

Published: 2013

Journal Articles

EBV DNA: a Hodgkin lymphoma biomarker?

Ralph M. Meyer

Blood (2013) 121 (18): 3541–3542.

https://doi.org/10.1182/blood-2013-02-484451

Published: 2013

Journal Articles

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial

Blood (2013) 121 (9): 1517–1523.

https://doi.org/10.1182/blood-2012-09-451872

Published: 2013

Journal Articles

Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy

Ralph M. Meyer, Richard T. Hoppe

Blood (2012) 120 (23): 4488–4495.

https://doi.org/10.1182/blood-2012-05-423236

Published: 2012

Journal Articles

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Blood (2012) 120 (21): 745.

https://doi.org/10.1182/blood.V120.21.745.745

Published: 2012

Journal Articles

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Blood (2012) 120 (21): 548.

https://doi.org/10.1182/blood.V120.21.548.548

Published: 2012

Journal Articles

A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia

Donald M. Arnold, Nancy M. Heddle, Julie Carruthers, Deborah J. Cook, Mark A. Crowther, Ralph M. Meyer, Yang Liu, Richard J. Cook, Anne McLeod, Janet A. MacEachern, Joy Mangel, David Anderson, Linda Vickars, Alan Tinmouth, Andre C. Schuh, John G. Kelton

Blood (2012) 119 (6): 1356–1362.

https://doi.org/10.1182/blood-2011-08-374777

Published: 2012

Journal Articles

Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6

Ralph M. Meyer, MD, Mary Gospodarowicz, MD, Joseph M. Connors, MD, Robert G Pearcey, MD, Woodrow A Wells, MD, Jane N. Winter, MD, Sandra J. Horning, MD, A. Rashid Dar, MD, Chaim Shustik, MD, Douglas A. Stewart, MD, Michael Crump, MD, FRCPC, Marina S Djurfeldt, MSc, Bingshu E Chen, PhD, Lois E Shepherd, M.D.

Blood (2011) 118 (21): 590.

https://doi.org/10.1182/blood.V118.21.590.590

Published: 2011

Journal Articles

Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials

Benjamin Djulbegovic, MD, PhD, Ambuj Kumar, MD, MPH, Branko Miladinovic, PhD, Asmita Mhaskar, MPH, Tea Reljic, BS, Sanja Galeb, BS, Rahul Mhaskar, MPH, PhD, Hozo Iztok, PhD, Dongsheng Tu, Heather Stanton, Christopher M Booth, Ralph M. Meyer, MD

Blood (2011) 118 (21): 508.

https://doi.org/10.1182/blood.V118.21.508.508

Published: 2011

Journal Articles

A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial

A. Keith Stewart, Suzanne Trudel, MD, MSC, FRCPC, Nizar J Bahlis, MD, Darrell J White, MD, Waleed Sabry, MSc, MD, Andrew Belch, MD, Tony Reiman, MD, Jean Roy, MD, FRCPC, Chaim Shustik, MD, Michael J. Kovacs, MD, FRCPC, Jonathan Sussman, Ralph M. Meyer, MD, Erica L Harnett, M.Sc., Danila Oana, Judy A Chapman, Lois Shepherd, MD

Blood (2010) 116 (21): 39.

https://doi.org/10.1182/blood.V116.21.39.39

Published: 2010

Journal Articles

A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease

Sten Myrehaug, Melania Pintilie, Lingsong Yun, Michael Crump, Richard W. Tsang, Ralph M. Meyer, Jonathan Sussman, Eric Yu, David C. Hodgson

Blood (2010) 116 (13): 2237–2240.

https://doi.org/10.1182/blood-2010-01-263764

Published: 2010

Journal Articles

Passive Transfer of Hepatitis B Core Antibody by Intravenous Immune Globulin in Patients with Immune Thrombocytopenic Purpura.

Donald M. Arnold, MDCM, MSc, Julie Carruthers, Julie DiTomasso, Thea Gagliardi, Ralph M. Meyer, MD, Mark A. Crowther, MD, John G. Kelton, MD, FRCPC

Blood (2009) 114 (22): 2418.

https://doi.org/10.1182/blood.V114.22.2418.2418

Published: 2009

Journal Articles

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial

Darrell J White, MD, Nizar J Bahlis, MD, Deborah C Marcellus, MD, Andrew Belch, MD, A. Keith Stewart, MBChB, MBA, Christine Chen, MD, Michael J Kovacs, MD, David A Macdonald, MD, Donna E Reece, MD, Erica Harnett, MSc, Judy-Anne W Chapman, PhD, Ralph M Meyer, MD

Blood (2008) 112 (11): 2767.

https://doi.org/10.1182/blood.V112.11.2767.2767

Published: 2008

Journal Articles

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.

Darrell J. White, MD, Michael J. Kovacs, MD, Andrew Belch, MD, Keith Stewart, MB, ChB, Christine Chen, MD, Sheldon Rubin, MD, David A. Macdonald, MD, Erica Harnett, MSc, Judy-Anne W. Chapman, PhD, Lois E. Shepherd, MD, Ralph M. Meyer, MD

Blood (2007) 110 (11): 189.

https://doi.org/10.1182/blood.V110.11.189.189

Published: 2007

NARROW

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Interpretation and Application of the International Myeloma Working Group (IMWG) Criteria: Proposal for Uniform Assessment and Reporting in Clinical Trials Based on the First Study Independent Response Adjudication Committee (IRAC) Experience

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

EBV DNA: a Hodgkin lymphoma biomarker?

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial

Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia

Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6

Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials

A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial

A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease

Passive Transfer of Hepatitis B Core Antibody by Intravenous Immune Globulin in Patients with Immune Thrombocytopenic Purpura.

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only